M. Kang

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).

J. Kim, J. Cheon, S. Lim, 2021, ESMO open.

Long-term mortality of patients with tuberculosis in Korea.

Y. Kang, C. Han, C. J. Kim, 2020, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

M. Ryu, S. Rha, B. Ryoo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

55P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)

G. Abou-Alfa, J. Lee, B. Ryoo, 2022, Annals of Oncology.